Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells

Breast Cancer Research

Volumn 12, Issue 3, 2010, Pages

  Paris, Luisa ^a   Cecchetti, Serena ^a   Spadaro, Francesca ^a   Abalsamo, Laura ^a   Lugini, Luana ^a   Pisanu, Maria Elena ^a   Iorio, Egidio ^a   Natali, Pier Giorgio ^b   Ramoni, Carlo ^a   Podo, Franca ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLCHOLINE SPECIFIC PHOSPHOLIPASE C; PHOSPHODIESTERASE; PHOSPHOLIPASE C; TRASTUZUMAB; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLCHOLINE-SPECIFIC PHOSPHOLIPASE C;

ARTICLE; BIOTINYLATION; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CYTOMETRY; DOWN REGULATION; ENDOCYTOSIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIPID RAFT; LYSOSOME; NONHUMAN; PROTEIN EXPRESSION; BREAST; BREAST TUMOR; CELL CULTURE; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CELL MEMBRANE; CELL PROLIFERATION; CELLS, CULTURED; ENDOCYTOSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYSOSOMES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TYPE C PHOSPHOLIPASES;

EID: 78149472495     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2575     Document Type: Article

References (70)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137. 10.1038/35052073, 11252954.
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787-2799. 10.1200/JCO.2003.01.504, 12860957.
3. Lemmon MA. The EGF receptor family as therapeutic targets in breast cancer. Breast Dis 2003, 18:33-43.
4. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
5. Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C. HER2 expression in breast cancer primary tumours and corresponding metastases: original data and literature review. Br J Cancer 2004, 90:2344-2348. 2409528, 15150568.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
7. Sjögren S, Inganãs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998, 16:462-469.
8. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65. 10.1016/S0014-4827(02)00101-5, 12648465.
9. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287. 231527, 8816440.
10. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis. J Biol Chem 2003, 278:23343-23351. 10.1074/jbc.M300477200, 12686539.
11. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J 1997, 16:1647-1655. 10.1093/emboj/16.7.1647, 1169769, 9130710.
12. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996, 271:5251-5257. 10.1074/jbc.271.31.18989, 8617810.
13. Lenferink AE, Pinkas-Kramarski R, Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998, 17:3385-3397. 10.1093/emboj/17.12.3385, 1170676, 9628875.
14. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999, 274:8865-8874. 10.1074/jbc.274.13.8865, 10085130.
15. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 1996, 271:19029-19032. 10.1074/jbc.271.32.19029, 8702572.
16. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001, 28:13-19. 10.1016/S0093-7754(01)90188-5, 11301370.
17. Lin A, Rugo HS. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol 2007, 8:47-60. 10.1007/s11864-007-0008-2, 17660958.
18. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44:2806-2812. 10.1016/j.ejca.2008.09.013, 19022660.
19. Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008, 17:499-505. 10.1016/j.breast.2008.03.006, 18450443.
20. Bayo-Calero JL, Mayordomo JI, Sánchez-Rovira P, Pérez-Carrión R, Illaramendi JJ, García-Bueno JM, González-Flores E, Crespo C, Ramos-Vázquez M, García-Palomo A, Ruiz-Borrego M, de la Haba J, Gómez-Bernal A, Yubero-Esteban A. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 2008, 8:264-268. 10.3816/CBC.2008.n.030, 18650157.
21. Perez EA, Baweja M. HER-2-positive breast cancer: current treatment strategies. Cancer Invest 2008, 26:545-552. 10.1080/07357900801971024, 18584344.
22. Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008, 26:3317-3323. 10.1200/JCO.2007.13.5202, 18490651.
23. Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA. Assessment of epidermal growth factor receptor with 99 mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003, 14:49-56. 10.1097/00001813-200301000-00007, 12544258.
24. Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, Cocklin S, Williams JC, Papazoglou E, Rodeck U. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008, 7:726-733.
25. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64:6652-6659. 10.1158/0008-5472.CAN-04-1168, 15374980.
26. Widakowich C, De Castro G, De Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. The Oncologist 2007, 12:1443-1455. 10.1634/theoncologist.12-12-1443, 18165622.
27. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
28. Huang Z, Brdlik C, Jin P, Shepard HM. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 2009, 9:97-110. 10.1517/14712590802630427, 19063696.
29. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V, Band H. A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 2008, 7:1630-1640. 10.1158/1535-7163.MCT-07-2409, 2727620, 18769124.
30. Bache KG, Salgsvold T, Stenmark H. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J 2004, 23:2707-2712. 10.1038/sj.emboj.7600292, 514952, 15229652.
31. Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008, 8:392-401. 10.3816/CBC.2008.n.047, 18952552.
32. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525-3533. 10.1200/JCO.2007.11.0106, 17687157.
33. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22. full_text, 17993229.
34. Negendank WG. Studies of human tumors by MRS: a review. NMR Biomed 1992, 5:303-324.
35. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999, 12:413-439. 10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U, 10654290.
36. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005, 65:9369-9376. 10.1158/0008-5472.CAN-05-1146, 16230400.
37. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006, 3:496-506. 10.1021/mp060067e, 17009848.
38. Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Fausto A, Canevari S. Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr Mol Imaging Rev 2007, 3:123-137.
39. Ramoni C, Spadaro F, Barletta B, Dupuis ML, Podo F. Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp Cell Res 2004, 299:370-372. 10.1016/j.yexcr.2004.05.037, 15350536.
40. Cecchetti S, Spadaro F, Lugini L, Podo F, Ramoni C. Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur J Immunol 2007, 37:2912-2922. 10.1002/eji.200737266, 17899539.
41. Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res 2008, 68:6541-6549. 10.1158/0008-5472.CAN-07-6763, 18701477.
42. Clark MA, Shorr RG, Bomalaski JS. Antibodies prepared to Bacillus cereus phospholipases C cross react with a phosphatidylcholine preferring phospholipases C in mammalian cells. Biochem Biophys Res Commun 1986, 140:114-119. 10.1016/0006-291X(86)91065-X, 3096314.
43. Podo F, Ferretti A, Knijn A, Zhang P, Ramoni C, Barletta B, Pini C, Baccarini S, Pulciani S. Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res 1996, 16:1399-1412.
44. Ramoni C, Spadaro F, Menegon M, Podo F. Cellular localization and functional role of phosphatidylcholine-specific phospholipase C in NK cells. J Immunol 2001, 167:2642-2650.
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
46. Rubinstein LV, Shoemaker RH, Paull KD, Simm RM, Tosini S, Skehan P, Scadiero DA, Momks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990, 82:1113-1120. 10.1093/jnci/82.13.1113, 2359137.
47. Spadaro F, Cecchetti S, Sanchez M, Ausiello CM, Podo F, Ramoni C. Expression and role of phosphatidylcholine-specific phospholipase C in human NK and T-lymphocyte subsets. Eur J Immunol 2006, 36:3277-3287. 10.1002/eji.200635927, 17111345.
48. Sargiacomo M, Sudol M, Tang Z, Lisanti MP. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993, 122:789-807. 10.1083/jcb.122.4.789, 2119592, 8349730.
49. Zhu W, Okollie B, Artemov D. Controlled internalization of Her-2/neu receptors by cross-linking for targeted delivery. Cancer Biol Ther 2007, 6:1960-1966. 10.4161/cbt.6.12.4979, 18075296.
50. Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 1995, 92:3353-3357. 10.1073/pnas.92.8.3353, 42164, 7724565.
51. Longva KE, Pedersen NM, Haslekas C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005, 116:359-367. 10.1002/ijc.21015, 15800944.
52. Ginester C, Adélaïde J, Gonçalves A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertuci F, Jacquemier J, Viens P, Birnbaum D. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 2007, 26:7163-7169. 10.1038/sj.onc.1210528, 17525746.
53. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J 1995, 14:5859-5868. 394704, 8846779.
54. Liu X, Zhao Q, Araki S, Zhang S, Miao J. Contrasting effects of phosphatidylcholine-specific phospholipase C on apoptosis in cultured endothelial cells. Endothelium 2006, 13:205-211. 10.1080/10623320600760423, 16840176.
55. Zhao J, Zhao B, Wang W, Huang B, Zhang S, Miao J. Phosphatidylcholine-specific phospholipase C and ROS were involved in chicken blastodisc differentiation to vascular endothelial cell. J Cell Biochem 2007, 102:421-428. 10.1002/jcb.21301, 17393430.
56. Wang N, Xie K, Huo S, Zhao J, Zhang S, Miao J. Suppressing phosphatidylcholine-specific phospholipase C and elevating ROS level, NADPH oxidase activity and Rb level induced neuronal differentiation in mesenchymal stem cells. J Cell Biochem 2007, 100:1548-1557. 10.1002/jcb.21139, 17211851.
57. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276. 10.1158/0008-5472.CAN-03-3829, 15205341.
58. Kappler LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-cbl and enhancing ubiquitinylation of HER2. Cancer Res 2000, 60:3384-3388.
59. Beerli RR, Wels W, Hynes NE. Intracellular expression of single-chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994, 269:23931-23936.
60. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signalling. Mol Cell Biol 1995, 15:1182-1191. 230341, 7532277.
61. Le XF, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005, 4:87-95.
62. Tamura K, Rice RL, Wipf P, Lazo JS. Dual G1 and G2/M phase inhibition by SC-ααδ9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene 1999, 18:6989-6996. 10.1038/sj.onc.1203179, 10597298.
63. Vogt A, Pestell KE, Day BW, Lazo JS, Wipf P. The antisignaling agent SC-ααδ9,4-(benzy-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl-2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity. Mol Cancer Ther 2002, 1:885-892.
64. Franklin CL, Li H, Martin SF. Design, synthesis, and evaluation of water-soluble phospholipid analogues as inhibitors of phospholipase C from Bacillus cereus. J Org Chem 2003, 68:7298-7307. 10.1021/jo034411k, 12968879.
65. Gonzalez-Roura A, Casas J, Llebaria A. Synthesis and phospholipase C inhibitory activity of D609 diastereomers. Lipids 2002, 37:401-406. 10.1007/s1145-002-0908-0, 12030321.
66. Müller-Decker K, Doppler C, Amtmann E, Sauer G. Interruption of growth signal transduction by an antiviral and antitumoral xanthate compound. Exp Cell Res 1988, 177:295-302. 10.1016/0014-4827(88)90463-6, 2839351.
67. Müller-Decker K. Interruption of TPA-induced signals by an antiviral and antitumoral xanthate compound: inhibition of a phospholipase C type reaction. Biochem Biophys Res Commun 1989, 162:198-205. 10.1016/0006-291X(89)91981-5, 2751648.
68. Amtmann E, Sauer G. Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogenate and lauric acid. Int J Cancer 1990, 45:1113-1118. 10.1002/ijc.2910450621, 2141005.
69. Sauer G, Amtmann E, Hofmann W. Systemic treatment of a human epidermoid non-small cell lung carcinoma xenograft with a xanthate compound causes extensive intratumoral necrosis. Cancer Letters 1990, 53:97-102. 10.1016/0304-3835(90)90200-H, 2170004.
70. Amtmann E. The antiviral, antitumoral xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res 1996, 22:287-294.